Made Scientific, a leading contract development and manufacturing organization (CDMO) for clinical and commercial cell therapies, and Streamline Bio, a next-generation autonomous robotics company addressing critical challenges in cell and gene therapy (CGT) manufacturing, announced successful initial validation of Streamline Bio’s AI-driven precision robotics platform in a live cell therapy production setting.
Following the successful completion of initial validation at Made Scientific’s Princeton, NJ facility, the two companies are now advancing toward GMP integration, including the launch of early-adopter programs. The collaboration aims to deploy Streamline Bio’s fully robotic manufacturing solution for cell therapy innovators, tackling major industry bottlenecks such as production complexity, high costs, and variable quality of therapies.
Unlike conventional, infrastructure-heavy robotic automation systems, Streamline Bio’s platform is purpose-built for multi-step cell therapy production. Its flexible design allows immediate adaptability across diverse equipment and protocols, minimizing the need for process changes, custom configurations, or additional parts. By automating labor-intensive, manual processes, the platform reduces operator burden, mitigates human error, lowers production costs, and enables skilled personnel to focus on higher-value activities all while maintaining full data traceability through a digital-first approach.
Also Read: Medra Unveils Continuous Science Platform for Research
The next phase of collaboration will focus on preparing the platform for GMP deployment with Miltenyi CliniMACS Prodigy®, G-Rex®, and Fresenius-Kabi LOVO® systems. Streamline Bio’s fully robotic solution, now validated in a live manufacturing environment, will integrate into Made Scientific’s GMP cleanrooms, orchestrating complex workflows seamlessly and paving the way for commercial-scale implementation. Future studies will expand verification to additional unit operations, including automated analytical and quality control testing workflows.
“Today’s CGT processes are incredibly nuanced and complex,” said Rodney Rietze, Ph.D., President & CEO of Streamline Bio. “Streamline Bio’s robotic platform allows cell and gene therapy developers and manufacturers to respond with automation that’s not only smart and scalable, but inherently adaptive – enabling it to seamlessly integrate into your existing infrastructure with minimal costs and no workflow restrictions.”
“Streamline Bio is redefining manufacturing by offering an innovative, flexible and scalable platform aimed at making transformative therapies more accessible to patients,” said Syed T. Husain, Chairman & CEO of Made Scientific. “We’re excited to partner together as the companies explore how their technology can ultimately impact cost, process and product reproducibility and time-to-clinic for emerging therapies.”